BA1301 / Luye Group, Shandong Boan Biotechnology - LARVOL DELTA

CT-CHN-101: Phase I clinical trial of BA1301 injection for the treatment of patients with advanced solid tumors (clinicaltrials.gov) - P1 | N=222 | Recruiting | Sponsor: Shandong Boan Biotechnology Co., Ltd. | -> Recruiting | Phase classification: PN/A ➔ P1

Enrollment open • First-in-human • Phase classification • Cholangiocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • CLDN18

CLDN18.2–targeting antibody-drug conjugate BA1301 in advanced solid tumors: Results from a phase I clinical trial. (ASCO 2026) - P1 | "BA1301 was well-tolerated with a manageable safety profile and demonstrated promising anti-tumor activity in patients with CLDN18.2 moderate to high expression. The findings support further development of BA1301 as a new therapeutic approach to treat CLDN18.2-positive solid tumors. The trial (NCT06927349) is ongoing in China."

ADC • Clinical • Metastases • P1 data • Biliary Cancer • Biliary Tract Cancer • Gastric Cancer • Gynecologic Cancers • Oncology • Ophthalmology • Pancreatic Cancer • Solid Tumor • CLDN18

First-in-human study of BA1301, a novel CLDN18.2-targeting antibody-drug conjugate in advanced solid tumors (ESMO 2025) - P1 | "Hematologic and gastrointestinal toxicities were significantly lower than other CLDN18.2-targeting ADCs,and ocular toxicity was also substantially reduced compared to the ADC A166 with the same payload Duo-5. Encouraging antitumor activity was observed in heavily pre-treated Gastric Cancer, Cholangiocarcinoma and Pancreatic Cancer with CLDN18.2 medium or high expression. Based on the positive efficacy data and good long-term safety, further trials of BA1301 as monotherapy or in combination with nivolumab are being planned."

First-in-human • Metastases • P1 data • Biliary Cancer • Cholangiocarcinoma • Gastric Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CLDN18

Tularemia orchitis following pneumonic tularemia: a histopatho-logically confirmed case in a patient under TNF(tumour necrosis factor)-α inhibition (ECP 2025) - " A 71-year-old male with psoriatic arthritis on adalimumab was diagnosed with pneumonic tularemia, confirmed by blood cultures... This is the second histopathologically confirmed case of tularemia orchitis worldwide. In immunosuppressed patients, especially those under TNF-α inhibition, F. tularensis should be considered in atypical inflammatory presentations. Orchiectomy combined with extended antibiotic treatment (doxycycline and ciprofloxacin) resulted in remission."

Clinical • Germ Cell Tumors • Immunology • Infectious Disease • Inflammatory Arthritis • Oncology • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • CD163 • CD20 • CD68 • POU5F1 • PTPRC • SALL4

DLL3 expression in small round cell tumors: a potential therapeutic target for SMARCA4-deficient tumors (ECP 2025) - "Rova-T demonstrated dose-dependent efficacy against both H661 (IC50=0.07686 μM) and H82 (IC50=0.1061 μM), with BEAS-2B showing similar sensitivity (IC50=0.09885 μM)... DLL3 is expressed in a subset of SRTs, with significantly higher rates in SMARCA4-dUT. The association between DLL3 and synaptophysin suggests neuroendocrine differentiation. These findings identify DLL3 as a potential therapeutic target for SMARCA4-dUTs, warranting further investigation the absence of survival differences in our clinical cohort."

Ewing Sarcoma • Lung Cancer • Neuroblastoma • NUT Midline Carcinoma • Oncology • Rhabdoid Tumor • Rhabdomyosarcoma • Sarcoma • Small Cell Lung Cancer • Soft Tissue Sarcoma • Solid Tumor • Synovial Sarcoma • DLL3 • SMARCA4 • SMARCB1 • SYP

Tumour heterogeneity and prognostic significance of PD-L1 expression according to the durvalumab companion VENTANA (SP263) assay in metastasizing urothelial bladder carcinoma (ECP 2025) - "Primary-to-metastatic conversion of the PD-L1 score occurred in 20.2% of patients, and testing both components might improve patient selection for immune checkpoint therapies. A favourable OS for patients with high PD-L1 scores is compatible with tumour suppressive effects, as recently described for this biomarker."

Heterogeneity • IO biomarker • Metastases • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • PD-L1

A RARE CASE OF CHYLOTHORAX SECONDARY TO THE PERIVASCULAR EPITHELIOD CELL TUMOR (PEComa): DIAGNOSTIC AND THERAPEUTIC CHALLENGES (MTS 2025) - "Early recognition through appropriate analysis of pleural fluid enables a timely diagnosis. Effective conservative management, together with targeted therapy with everolimus shows an excellent outcome for PEComa."

Clinical • Chronic Cough • Cough • Hematological Disorders • Oncology • Pulmonary Disease • Respiratory Diseases

RARE AND AGGRESIVE: MEDIASTINAL YOLC SAC TUMORS COMPLICATED BY SUPERIOR VANE CAVA SYNDROME – A CASE SERIES (MTS 2025) - "Initial management included supportive care with dexamethasone and furosemide to reduce SVCS symptoms, followed by chemotherapy with the BEP (Bleomycin, Etoposide, Platinum based) regimen for two patients...Early diagnosis, prompt management of SVCS, and a multidisciplinary approach to treatment are essential for improving outcomes. However, despite aggressive treatment, the overall survival remains low, as demonstrated in this case series."

Clinical • Germ Cell Tumors • Oncology • Respiratory Diseases • Testicular Non-seminoma

PD-L1 expression in neuroendocrine urothelial and prostate tumours (ECP 2025) - "Recent studies, including a phase 1b trial combining pembrolizumab with platinum-based chemotherapy, have shown promising results for stage III-IV SCNECs... This study is the first to evaluate PD-L1 expression in genitourinary SCNECs. While expression varied, bladder-origin tumours showed higher PD-L1 positivity compared to prostate-origin tumours. These findings suggest that bladder-origin SCNECs may benefit from immunotherapy, though larger studies are needed to confirm these results."

IO biomarker • Bladder Cancer • Endocrine Cancer • Neuroendocrine Carcinoma • Oncology • Prostate Cancer • Solid Tumor • Urothelial Cancer • PD-L1

Personalising outcomes with patient-derived tumour organoid (PDTO) anal squamous cell carcinoma (ASCC) models (ESCP 2025) - "Molecular directed therapies with alpelisib (PI3-kinase inhibitor) or abemaciclib (CDK4/6 inhibitor) demonstrated efficacy against PDTOs with PIK3CA mutation or p16 loss, respectively...Co-culture studies with HER2 CAR-T cells demonstrated cytotoxicity against HER2 positive organoids, which was enhanced by anti-PD-1 blockade. Conclusion This world first PDTO biobank is an invaluable translational platform for disease modelling and can be utilised in future co clinical trials to interrogate vulnerabilities in relapsed ASCC."

Clinical • IO biomarker • Anal Carcinoma • Oncology • Squamous Cell Carcinoma • EP300 • HER-2 • KMT2D • MUC4 • PIK3CA • SOX2 • TP53 • TP63

A SILENT TUMOR, A STRANGED VEIN: LUNG ADENOCARCINOMA PRESENTING AS SUPERIOR VENA CAVA SUNDROME (MTS 2025) - "She was subsequently initiated on Ceritinib 300 mg once daily...Given the patient's Kishi score of 5, the decision to proceed with stenting was considered due to the rapid improvement of symptoms. This case report describes an unusual presentation of advanced adenocarcinoma of the lung with superior vena cava syndrome, which is successfully managed with endovascular stenting."

Cough • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Respiratory Diseases • Solid Tumor • ALK

The role of PCSK9 in tumor microenvironment and drug resistance in Hepatocellular carcinoma (ECP 2025) - "Conversely, PCSK9 expression is markedly upregulated in sorafenib-resistant HepG2 cells... In conclusion, this study aims to explore the molecular mechanisms and clinical significance underlying driving PCSK9 expression in resistance development and explore the interplay between the tumor microenvironment (TME) and HCC, ultimately leading to the development of more effective therapeutic strategies for HCC treatment."

Biomarker • Tumor microenvironment • Hepatocellular Cancer • Oncology • Solid Tumor • IL6 • PCSK9

Primary mediastinal yolk sac tumour: case presentation with molecular study by sequencing (ECP 2025) - "Primary Mediastinal Yolk Sac Tumour presents significant diagnostic complexity due to its rarity and its aggressive clinical behaviour, often leading to confusion with other mediastinal tumours. The molecular profile, including TP53 mutations, is distinct from that of testicular germ cell tumours and plays a key role in the prognosis. TP53 mutations are reported in up to 82% of cases and are considered a prognostic factor associated with resistance to cisplatin based therapies, adding another layer of complexity in the management of these tumours."

Clinical • Endocrine Cancer • Germ Cell Tumors • Hepatocellular Cancer • Large Cell Carcinoma • Lung Cancer • Neuroendocrine Carcinoma • NUT Midline Carcinoma • Oncology • Solid Tumor • Testicular Cancer • Testicular Seminoma • Thymic Carcinoma • Thymus Cancer • CDX2 • GATA3 • GPC3 • KIT • POU5F1 • PTEN • SALL4 • SYP • TNFRSF8 • TP53 • WT1

Intratumoral bacterial abundance confers poor response to adjuvant gemcitabine in resected pancreatic cancer patients which is mitigated by postoperative antibiotics (ECP 2025) - "High intratumoral bacterial abundance may predict poor response to adjuvant gemcitabine treatment, whereas postoperative ABT improves it. We propose postoperative ABT as potential additive treatment before or during aGC therapy after PDAC resection."

Clinical • Infectious Disease • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Impact of molecular profiling in the management of high-grade serous carcinoma: a case of tumour heterogeneity (ECP 2025) - "The CT scan showed no residual disease. The patient received 5 cycles of chemotherapy (carboplatin AUC5 + paclitaxel 175 mg/m²). Given the molecular heterogeneity observed, the best maintenance therapy remained uncertain."

Clinical • Heterogeneity • Gynecology • Oncology • BRCA1 • BRCA2 • HRD • MUTYH • TP53

MRI-detected extramural venous invasion and tumor deposits as independent predictors of distant metastasis in rectal cancer: A retrospective analysis from a tertiary Norwegian institution (ESCP 2025) - "Nearly all patients received long-course chemoradiotherapy, comprising 50.4–52 Gy, combined with radiosensitizing capecitabine or 5-FU...These findings support the use of MRI-based risk stratification in early treatment planning and emphasize the need for individualized therapeutic strategies. Further research should explore more extensive integration of MRI findings into clinical decision-making algorithms."

Retrospective data • Colorectal Cancer • Oncology • Rectal Cancer • Solid Tumor

Multiple gastrointestinal stromal tumours: a series of 27 patients (ECP 2025) - "There is no criteria to differenciate primary versus meta-static cases in the setting of multiple synchronous or metachronic GIST. The prognosis of Extra-GIST patients is worse than gastrointestinal GIST. Molecular analysis is recomended in multiple GIST to evaluate the presence and type of mutation and therefore the different sensitivity to imatinib"

Clinical • Stroma • Gastrointestinal Cancer • Gastrointestinal Disorder • Genetic Disorders • Neurofibromatosis • Oncology • Sarcoma • Solid Tumor • KIT • PDGFRA

Solitary fibrous tumor of the sigmoid colon: An exceptional localization (ESCP 2025) - "Conclusion SFT is rare outside the thoracic cavity, with a significant risk of recurrence and metastasis (up to 36%). In our patient, the presence of microscopically involved margins was considered a negative prognostic factor, which prompted us to complete the surgical resection to achieve an R0 status.Close, long-term follow-up is essential due to the tumor's potential aggressiveness."

Gynecologic Cancers • Gynecology • Oncology • CD34 • STAT6

Sarcomatoid metaplastic carcinoma or sarcoma: immunohisto-chemical analysis of CK-negative or -minimal positive sarcomatoid breast tumours (ECP 2025) - "Our study found that while sarcomatoid MBC may lose common epithelial markers, TRPS1 expression is consistently retained in these tumours (Group 1). The absence of CK, TRPS1, GATA3, and SOX10 may suggest primary sarcoma or terminal sarcomatoid differentiation of MBC, while the presence of TRPS1 with GATA3 and/or SOX10 supports an epithelial origin, such as MBC, potentially even in radiation-induced cases."

Breast Cancer • Oncology • Sarcoma • Solid Tumor • GATA3 • SOX10 • TRPS1

Monophasic gastric tumour with MALAT1-GLI1 fusion: another variant of gastroblastoma (ECP 2025) - "Due to their extremely low incidence and the lack of distinct characteristics, gastroblastomas pose a diagnostic challenge. Their biphasic nature, characterized by the presence of both epithelial and spindle cell components, normally serves as a key diagnostic criterion. However, in our case, as well as in two recently published clinical cases, a new variant of GLI1-rearranged gastrointestinal monophasic tumours is described."

Gastric Cancer • Hepatocellular Cancer • Hepatology • Oncology • Solid Tumor • ANO1 • CD34 • GLI1 • KIT • MALAT1 • MME • NCAM1 • SYP

Wolffian tumour of the broad ligament: a rare case with diagnostic challenges (ECP 2025) - "This case provides important insights into the broad ligament as a primary site for Wolffian tumours, a diagnosis that can be challenging in frozen section. It highlights the importance of precise clinical correlation to exclude involvement from an ovarian tumour."

Clinical • Gynecologic Cancers • Gynecology • Oncology • Ovarian Cancer • Skin Cancer • Solid Tumor • CD99 • GATA3 • PAX8 • SYP • WT1

Long-term outcome after neoadjuvant treatment of rectal cancer dependent on histopathological tumor regression using the Dworak grading system (ESCP 2025) - "Conclusion In our cohort of patients we found significant differences in both recurrence and survival rates according to TRG using the Dworak system. As different TRG systems have been used to date it would be desirable to use a standardised grading system to allow comparisons regarding the use of TRG as a surrogate parameter in neoadjuvantly treated rectal cancer."

Clinical • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Rectal Adenocarcinoma • Rectal Cancer • Solid Tumor

Round cell / epithelioid tumours part 2 (ECP 2025) - No abstract available

Oncology

Inflammatory myofibroblastic tumours of the urinary bladder: 25-year single-centre experience (ECP 2025) - "Inflammatory myofibroblastic tumour is a mesenchymal tumour that should be considered in the differential diagnosis of spindle cell lesions of the urinary bladder. Ancillary tests such as immunohistochemistry and fluorescence in situ hybridization for ALK are helpful in diagnosis."

Clinical • Bladder Cancer • Oncology • ALK

Assessment of primary tumour and metastatic focus in gynaeco-logical tumours that spread to the central nervous system (ECP 2025) - "In the realm of brain metastases, median survival is generally short, often lasting only months. This study assessed the distinction between primary tumours and brain metastases. In future studies, our goal is to improve our understanding of the differences between the primary tumour and the metastatic site."

Metastases • Breast Cancer • Cervical Cancer • Endometrial Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor